US FDA Gives RMAT Boost To AlloVir As Viralym-M Phase III Planning Continues
Executive Summary
Multi-virus specific T-cell brings the number of known RMAT awards to 29, as detailed in our updated RMAT tracker table. AlloVir's product aims to restore natural T-cell immunity in immunocompromised patients.
You may also be interested in...
Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
BIO 2019 Notebook: Merck; RMAT; Out-Licensing Deals
News and views from day one of the BIO International Convention: Merck reaffirms commitment to antibiotic space the same day Zerbaxa picks up a new indication; US FDA regenerative medicine advanced therapy designations now outnumber breakthrough designations for cell/gene therapies; BIO survey finds out-licensing cash for emerging firms more than doubled in 2018.
ElevateBio Announces AlloVir As First Spoke In Its Cell And Gene Therapy Hub
ElevateBio revealed the first company to hitch up with its newly established centralized cell and gene therapy development, manufacturing and commercial capabilities – AlloVir, formerly ViraCyte, which is developing T-cell therapies to treat viruses in immunocompromised patients.